Our multi year strategic partnership with @AstraZeneca is an important relationship to us. We presented results on machine learning in lung disease imaging to predict patient outcomes at this year's American Thoracic Society meeting in San Diego.
We’re working with @qureight to leverage AI to quantify radiological features in idiopathic pulmonary fibrosis. Learn more about our work in AI: https://t.co/Ev9YfbQRJF #ATS2024
We’re working with @qureight to leverage AI to quantify radiological features in idiopathic pulmonary fibrosis. Learn more about our work in AI: https://t.co/Ev9YfbQRJF #ATS2024
We will be attending the @atscommunity Conference (#ATS2024) this month in San Diego!
We're excited to catch up with fellow Respiratory research colleagues in the field!
Muhunthan T, Dan G & Simon W will be there, drop us an email to catch up over coffee☕️➡️[email protected]
Predicting progressive disease and mortality in IPF using automated analysis of CT scans. A massive collaborative effort between @ImperialNHLI@qureight & @AstraZeneca now in press @ATSBlueEditor#cureipf
https://t.co/me3Ulza28m
We had a great time at the Milner x @CamGravity Biotech Matchmaking event last week, and were delighted to welcome many of our affiliated companies there!
Don't miss the @CambridgeIndy piece linked below to find out more! 👇
https://t.co/8UTrl7qGhg
Congratulations to the latest additions to the #21toWatch longlists! Sam Nallaperuma (@sam123sam) Daniel de la Torre, Broderick House @AgriSynth@qureight@Cambrionix Vector Bioscience @WeAreWatr and UbisonOne System by Smart Acoustics https://t.co/rRl7t46PlU
Reall excited to announce the appointment of Dr. Xose Fernandez to our Scientific Advisory Board. He brings a wealth of experience in data strategy and will be transformative to our plans for growth.
https://t.co/YLlbNJ9Qcx
Today we announce that we have gained ISO13485 certification. A significant step forward in integrating our platform with clinical trials.
https://t.co/4P4La4wuKj
Announcing results from our first product (Lung8) at this year's @EuroRespSoc in Barcelona. Analysis of data from a @GalapagosGlobal phase 2 IPF study showed that we can do trials faster and cheaper in complex diseases.
https://t.co/SYbhU6gnQY #023 |
@innovateuk budget boosted to £1 billion.
#SevenlessTherapeutics has secured €1.3 million funding. @Qureight has announced its Scientific BoD. Liz McKee Anderson has joined @GSK Board of Directors.
This and more below👇🏽
https://t.co/DCbcF04ofy
https://t.co/SYbhU6gnQY #023 |
@innovateuk budget boosted to £1 billion.
#SevenlessTherapeutics has secured €1.3 million funding. @Qureight has announced its Scientific BoD. Liz McKee Anderson has joined @GSK Board of Directors.
This and more below👇🏽
https://t.co/DCbcF04ofy
Today we announce our IPF Scientific Advisory Board with leading global experts to help us implement our platform technology with a growing number of biopharma partners worldwide @TobyMMaher@drphilmol Paul Ford, Bill Bradford and Mel Wickremasinghe.
https://t.co/n3uT5h8ECg
Qureight has ranked in Business Cloud's Top 50 for the UK's most innovative MedTech creators for 2022! A great start to week, we love to see others sharing in our vision!
https://t.co/9jo1bTbXjC